Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children☆,☆☆,★,★★
Section snippets
Study design
This prospective, before-after study was performed during a regional health department vaccination campaign against serogroup C meningococcal disease involving 225,000 children, aged 6 months to 19.9 years, in eastern Ontario and western Quebec, Canada.20 The study was approved by our research ethics review committee and informed consent was obtained from all participants/guardians.
Study participants
Participants were 6 months to 19.9 years of age, eligible for the health department vaccination program, and
RESULTS
A total of 2240 children participated in this study with a median age of 4.7 years (range 6 months to 19.9 years) and a 1.1:1 male/female ratio. The median total family size was 4.0, number of children per household 2.1, and family income, derived from postal code data,26 $49,600 (Canadian). In comparison, our population's regional median family size was 3.8, number of children per household 1.2, and income $50,800 (Canadian).26, 27 At 1 month, 86% (1922) of the participants returned for
DISCUSSION
The vaccine used in this study was safe, confirming previous reports that the majority of side effects are minor and consist of transient reactions at the site of injection.28 Oropharyngeal carriage of N. meningitidis at the time of the serogroup C outbreak in our community was low, the majority of the isolates being of low virulence. This is consistent with previous reports documenting low carriage rates, particularly in young children, of both the involved clone and of total N. meningitidis
Acknowledgements
We thank Drs. Ian Gemmil and Steve Corber from the Ottawa-Carleton Regional Department of Health, Drs. Pierre Lavigne, Bob Wittes, and Luis Barreto from Connaught Laboratories Limited, and Dr. Doug Manion and Terry Sutcliffe for their assistance and support of this project.
References (35)
- et al.
Serogroup C meningococcal outbreaks in the United States
JAMA
(1995) - et al.
The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992
JAMA
(1995) Meningococcal disease: was Ottawa mass-vaccination program necessary?
Can Med Assoc J
(1992)Mass voluntary immunization campaigns for meningococcal disease in Canada: media hysteria
JAMA
(1992)- et al.
Issues in the control of outbreaks of group C meningococcal disease in the United States
Infect Dis Clin Pract
(1994) - et al.
Human immunity to the meningococcus. I. The role of humoral antibodies
J Exp Med
(1969) - et al.
Human immunity to the meningococcus. II. Development of natural immunity
J Exp Med
(1969) - et al.
Human immunity to the meningococcus. IV. Immunogenicity of group A and C meningococcal polysaccharides in humans volunteers
J Exp Med
(1969) - et al.
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants
J Clin Invest
(1975) - et al.
Meningococcal infections: field trial of group C meningococcal polysaccharide vaccine in 1969-70
Bull World Health Organ
(1971)
Serologic response to serogroup C meningococcal vaccine in Brazilian pre-school children
Rev Inst Med Trop Sao Paulo
Disease prevention by meningococcal group C polysaccharide vaccine in pre-school children [Abstract]
Pediatr Res
Evaluation of two tetravalent (A,C,Y,W-135) meningococcal vaccines in infants and children. A clinical study comparing immunogenicity of O-acetyl negative and O-acetyl positive group C polysaccharides
Pediatrics
Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization in infants and children
J Infect Dis
Immune response of human infants to polysaccharide vaccines of groups A and C Neisseria meningitidis
J Infect Dis
Persistence of antibody following immunization of children with group A and group C meningococcal polysaccharides
Pediatrics
Response of children to Neisseria meningitidis polysaccharide vaccines
J Infect Dis
Cited by (0)
- ☆
From the Department of Pediatrics, Children's Hospital Eastern Ontario, University of Ottawa, the Clinical Epidemiology Unit, Ottawa Civic Hospital, University of Ottawa, and the Bureau of Microbiology, Laboratory Centre for Disease Control, Ottawa, Ontario, Canada
- ☆☆
Supported by funding from Connaught Laboratories, the Ontario Ministry of Health, and the Research Institute of the Children's Hospital of Eastern Ontario with the exception of the laboratory investigations, which were performed in collaboration with the Bureau of Microbiology, Laboratory Centre for Disease Control, Ottawa, Ontario, Canada.
- ★
Reprint requests: W. James King, MD, FRCPC, c/o Ambulatory Care, Department of Pediatrics, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario K1H 8L1, Canada.
- ★★
0022-3476/96/$5.00 + 0 9/20/69627